A phase I, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumours

被引：0
|
作者：
Tolcher, A. W. [1 ]
Falchook, G. [2 ]
Bendell, J. C. [3 ]
Ungar, D. [4 ]
Boni, J. [4 ]
Chao, G. [4 ]
Patel, M. R. [3 ,5 ]
机构：
[1] NEXT Oncol, Clin Res, San Antonio, TX USA
[2] HealthONE, Drug Dev Program, Sarah Cannon Res Inst, Denver, CO USA
[3] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[4] ADC Therapeut Inc, Clin Dev, Murray Hill, NJ USA
[5] Florida Canc Specialists, Sarasota Drug Dev Unit, Sarasota, FL USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
468P
引用
收藏
页码：176 / +
页数：2
相关论文
共 50 条
  • [41] Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies
    Doi, Toshihiko
    Boku, Narikazu
    Onozawa, Yusuke
    Takahashi, Keishiro
    Kawaguchi, Osamu
    Ohtsu, Atsushi
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1390 - 1399
  • [42] AN OPEN-LABEL PHASE I DOSE-ESCALATION CLINICAL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC PROFILE AND PRELIMINARY EFFICACY OF VG161 IN PATIENTS WITH ADVANCED PRIMARY LIVER CANCER
    Shen, Yinan
    Shi, Guoming
    Liang, Xingmei
    Jin, Xinyan
    Wang, Youlei
    Wei, Guyue
    Chen, Yi
    Huang, Xiaoyong
    Lu, Jiacheng
    Xia, Huiqun
    Xiao, Miao
    Rahimian, Shah
    Zhao, Ronghua
    Li, Yuwei
    Lin, Danni
    Fang, Tian
    Chen, Wei
    Ma, Tao
    Bai, Xueli
    Liang, Tingbo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A725 - A725
  • [43] An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
    Simon, Marc A.
    Hanrott, Kate
    Budd, David C.
    Torres, Fernando
    Gruenig, Ekkehard
    Escribano-Subias, Pilar
    Meseguer, Manuel L.
    Halank, Michael
    Opitz, Christian
    Hall, David A.
    Hewens, Deborah
    Powley, William M.
    Siederer, Sarah
    Bayliffe, Andrew
    Lazaar, Aili L.
    Cahn, Anthony
    Rosenkranz, Stephan
    PULMONARY CIRCULATION, 2022, 12 (01)
  • [44] An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer
    Liu, Joyce
    Burris, Howard
    Wang, Judy S.
    Barroilhet, Lisa
    Gutierrez, Martin
    Wang, Yulei
    Vaze, Anjali
    Commerford, Renee
    Royer-Joo, Stephanie
    Choeurng, Voleak
    Humke, Eric
    Moore, Kathleen
    GYNECOLOGIC ONCOLOGY, 2021, 163 (03) : 473 - 480
  • [45] A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors.
    Park, Jong Chul
    Butler, Marcus O.
    Curti, Brendan D.
    Emens, Leisha A.
    Pastor, Danielle M.
    Elassal, Joseph
    Kaufman, Howard L.
    Kirkwood, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] OPEN-LABEL, DOSE-ESCALATION, PHASE 1 STUDY OF SAFETY AND PHARMACOKINETICS OF DICHLOR-PHENAMIDE IN HEALTHY VOLUNTEERS
    Cohen, F.
    MUSCLE & NERVE, 2017, 56 : S10 - S10
  • [47] A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours
    van Herpen, C. M. L.
    Eskens, F. A. L. M.
    de Jonge, M.
    Desar, I.
    Hooftman, L.
    Bone, E. A.
    Timmer-Bonte, J. N. H.
    Verweij, J.
    BRITISH JOURNAL OF CANCER, 2010, 103 (09) : 1362 - 1368
  • [48] A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours
    C M L van Herpen
    F A L M Eskens
    M de Jonge
    I Desar
    L Hooftman
    E A Bone
    J N H Timmer-Bonte
    J Verweij
    British Journal of Cancer, 2010, 103 : 1362 - 1368
  • [49] An open-label phase I study to evaluate the safety, tolerability and preliminary efficacy of YY001 in patients with advanced solid tumors
    Xue, Liqiong
    Tang, Wenbo
    Zhou, Huan
    Liu, Mulin
    Liu, Yuanyuan
    Wang, Jinhua
    Chen, Jianfeng
    Liu, Mingyao
    Guo, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Single-arm, open-label, dose-escalation phase I study to evaluate the safety of a herbal medicine SH003 in patients with solid cancer: a study protocol
    Cheon, Chunhoo
    Kang, Sohyeon
    Ko, Youme
    Kim, Mia
    Jang, Bo-Hyoung
    Shin, Yong-Cheol
    Ko, Seong-Gyu
    BMJ OPEN, 2018, 8 (08):
12345